Create a Free Profile
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
Next-Generation Protein Degraders (PROTACs and RIPTACs) When Cancer Stops Responding to Your Current Drug
A new kind of medicine that tells your cells to dispose of the protein driving a disease. Meet the practices exploring them and choose the ones you want.
Approved for Some Uses
One PROTAC, vepdegestrant, is FDA-approved for certain advanced breast cancers. Other PROTACs, RIPTACs and next-generation degraders are investigational.
Free to join. No card required.
What Are Protein Degraders?
Most medicines work by blocking a protein. A degrader works differently: one end grabs the problem protein and the other end recruits the cell’s own disposal system, which tags it and breaks it down. Because the protein is removed rather than blocked, degraders may work where resistance has developed to an older drug. These are called PROTACs.
RIPTACs go a step further. They connect a protein found mainly in cancer cells to a protein the cell needs to survive, which is meant to harm cancer cells while sparing healthy ones. Some long-used myeloma medicines turn out to work as degraders too, which is part of what started this field.
Conditions It’s Used or Studied For
Breast Cancer
Prostate Cancer
Blood Cancers
Other Cancers (In Trials)
Only your physician can say whether it is right for you.
Before You Match
What to Know
-
One Is Approved; Most Are in Trials
Vepdegestrant is approved for certain ESR1-mutated breast cancers. Other degraders are available through clinical trials, each with its own eligibility rules.
-
Often After Resistance
Many studies enroll people whose cancer has stopped responding to a standard targeted drug. Your treatment history matters.
-
Biomarkers May Be Required
Some studies need a specific mutation or marker. Ask whether testing has been done.
-
Mostly Pills
Most degraders in trials are taken by mouth, with regular visits and lab work.
More About Protein Degraders
Health e Match summarized this information from the sources listed below. It is general information, not medical advice.
Who Is a Candidate?
One degrader is FDA-approved: vepdegestrant, for adults with ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation that has progressed after at least one hormone therapy. An ESR1 test, often a blood-based liquid biopsy, confirms eligibility.
Other degraders are being studied in adults with advanced cancer that has stopped responding to standard treatment, including prostate cancer and certain blood cancers such as chronic lymphocytic leukemia.
Trials often require a specific mutation or marker and a record of which treatments you have already had. Each study sets its own criteria.
What to Expect
Vepdegestrant is a pill taken once a day with food. Most degraders in trials are also taken by mouth. Early-phase studies may test different doses in different groups and include extra blood draws to measure how the drug moves through the body.
Expect more frequent visits early on than with standard treatment.
Recovery and Follow-Up
Follow-up typically includes visits every one to four weeks at first, regular blood tests, and scans every two to three months to measure response.
Risks and Side Effects
Side effects depend on the protein being targeted. Reported effects include nausea, diarrhea, tiredness, and changes in blood counts or liver tests. Vepdegestrant’s labeling warns that it can affect heart rhythm and can harm an unborn baby. Because these medicines are new, some risks may not be known yet, which is why trials monitor closely.
Cost and Insurance
Vepdegestrant is an oral cancer medicine, usually covered under a pharmacy benefit with prior authorization; copays can be high, and manufacturer programs may help. In a trial, the investigational medicine is usually provided at no cost. Ask for the details in writing.
Choosing a Practice
Questions worth asking in your first conversation:
- What phase is the study, and are slots open now?
- Which earlier treatments are required, or exclude me?
- Do I need a specific mutation, and how will it be tested?
- How often will I need to visit during the first months?
Alternatives to Consider
For hormone receptor-positive breast cancer, alternatives include other hormone-based therapies, targeted combinations, antibody-drug conjugates and chemotherapy. For prostate cancer, options include other hormone therapies, PARP inhibitors, radioligand therapy and chemotherapy. For CLL, approved targeted pills and antibody combinations. Your oncologist can compare a degrader trial with these.
Sources
Find a Practice That Offers It
Searching for protein degraders usually means a long list of names and no way to tell who actually offers it. Here, you meet verified practices that treat what you listed, and you decide who to talk to.
We’ll Introduce You
We only introduce verified practices that treat what you listed.
Choose Each Other
Swipe on the ones you like. When they swipe back — it’s a match!
Free to join. No card required.
Questions
What Patients Ask
Are PROTACs FDA-approved?
One is. Vepdegestrant was approved in May 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that has progressed after hormone therapy. Other PROTACs and RIPTACs are investigational. Some older myeloma medicines were later found to work by degrading proteins.
How is a degrader different from a targeted therapy?
A targeted therapy blocks a protein. A degrader removes it, which may help where a cancer has found a way around a blocking drug.
Who is a good candidate?
That depends on the study and on your diagnosis and history. A practice running a degrader trial can tell you whether you may be eligible.
What should I list on my profile?
Your diagnosis, the treatments you have had and how you responded, any mutation you know about, and that you are exploring protein degraders.
Start Matching Today
Build a free profile in minutes. List what you’re living with and that you’re exploring protein degraders, and meet the practices that treat it.
Free to join. No card required.
This page is general information, not medical advice, and it was last updated October 15, 2026. healthematch.com makes introductions between patients and practices in the United States. It does not provide medical care, does not enroll anyone in clinical research, and does not recommend any particular procedure or provider. Where a practice has documented a therapy’s regulatory status, it is shown exactly as documented. Are you a practice? See the protein degraders page for practices.